Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment.

Our mission is to develop therapies that create a profound, positive impact on patients’ lives. We challenge conventional thinking with a bold, patient-first mindset, driving meaningful progress in cancer treatment and fearlessly tackling challenges others may not. We lead with compassion, transparency, and passion to deliver treatments that redefine cancer care.

Our product and pipeline include differentiated and novel oncology treatments that have been generated from our proprietary drug discovery and development programs and acquired through business development activities. We were founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation Inc., which brought patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai.